Autopsy report · NCT05722522
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Cause of deathFunding or business
“Project discontinued to prioritize other key programs in portfolio”
Life of this trial
- Registered 6 months before it started.
- Ran for about 1 year 4 months before it stopped.
- 33 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Rotator Cuff Tendinopathy
- Interventions
- Secukinumab; Placebo
- Participants
- 33
- Sites
- 15
- Countries
- Argentina, Bulgaria, Canada, Czechia, Malaysia, Portugal, United States
Trials that died the same way
- HPV16 E6 TCR T Cells for Cervical Carcinoma
“Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs” - Safety Study of SEA-CD40 in Cancer Patients
“Study closed due to portfolio prioritization” - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
“Portfolio re-prioritization” - A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
“termination due to portfolio prioritization”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.